On top of directly targeting tubular cells to inhibit EMT, SCM would possess additional anti-inflammatory function in vivo to target the mobilization of immune cells by inhibiting pro-inflammatory factors, such as MCP-1, which would inhibit inflammation and further attenuate EMT in vivo in CKD. This evidence concerns the gene CCL2 and chronic kidney disease.